- Home
- POR vs BLTE Comparison
POR vs BLTE Comparison
Compare POR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | POR | BLTE |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United States | United States |
| Employees | 2915 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.0B |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | POR | BLTE |
|---|---|---|
| Price | $50.76 | $162.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $48.55 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 1.1M | 154.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $3,576,000,000.00 | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $5.83 | $492.11 |
| P/E Ratio | $51.89 | ★ N/A |
| Revenue Growth | ★ 3.95 | N/A |
| 52 Week Low | $41.80 | $60.00 |
| 52 Week High | $54.62 | $200.00 |
Technical Indicators
Market Signals| Indicator | POR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 51.55 |
| Support Level | $50.29 | $146.94 |
| Resistance Level | $51.43 | $172.02 |
| Average True Range (ATR) | 1.02 | 6.89 |
| MACD | 0.03 | 0.61 |
| Stochastic Oscillator | 69.22 | 32.39 |
Price Performance
Historical ComparisonAbout POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two-thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.6 gigawatts of gas, coal, wind, and hydro generation, along with 300 megawatts of energy storage. In February 2026, PGE proposed acquiring utilities in Washington state from Berkshire Hathaway Energy.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.